CLINICAL_TRIALS
trial_result
· 2022-10-31
Clinical Trial Update: A Study of CS1001 in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma [Phase 2]
Summary
Phase 2 clinical trial update for CS1001 in relapsed or refractory classical Hodgkin lymphoma has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: CStone Pharmaceuticals | Conditions: Hodgkin Lymphoma | Phase 2 | Status: COMPLETED